Title:Domperidone-associated Ventricular Arrhythmia and Sudden Cardiac Death: A
Descriptive Literature Review
Volume: 5
Author(s): Naina Mohamed Pakkir Maideen*, Ibrahim Ramadan Barakat and Abdurazak Hassan Jumale
Affiliation:
- Dubai Academic Health Corporation, Dubai, UAE
Keywords:
Domperidone, Cardiotoxicity, QT prolongation, Cardiac arrhythmia, Torsades de pointes, Ventricular arrhythmia, Sudden cardiac death.
Abstract:
Background:
Domperidone is an antiemetic and prokinetic agent that is widely used to treat nausea and vomiting, gastroparesis, and as a galactagogue.
Objective:
This review article focuses on QT prolongation, torsades de pointes, severe ventricular arrhythmia, and sudden cardiac death associated with the
use of domperidone or domperidone-containing products.
Methods:
The online databases, such as Medline/Pubmed/PMC, Google Scholar, Science Direct, Ebsco, Scopus, Web of Science, Embase, and reference
lists, were searched using keywords like Domperidone, Cardiotoxicity, QT prolongation, Cardiac arrhythmia, Torsades de pointes, Ventricular
arrhythmia, and Sudden Cardiac Death, to identify published articles relevant to domperidone-associated cardiotoxicity.
Results:
Domperidone has been linked to an increased risk of QT prolongation, torsades de pointes, severe ventricular arrhythmia, and sudden cardiac
death, according to a number of epidemiological studies and meta-analyses.
Conclusion:
Domperidone can only be used to treat nausea and vomiting in patients between the ages of 12 and 60, and a maximum daily dose of 30 mg has
been set by a number of regulatory bodies. The risk of severe ventricular arrhythmia and sudden cardiac death caused by domperidone should be
made clear to clinicians along with the recommendations from regulatory bodies to avoid any potential complications.
